Amy Duffield相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation

FLT3 酪氨酸激酶抑制剂与 BCL-2 抑制剂协同作用，通过 BIM 激活消除 FLT3/ITD 急性白血病细胞

期刊:Signal Transduction and Targeted Therapy

影响因子:40.8

doi:10.1038/s41392-021-00578-4

Ruiqi Zhu, Li Li, Bao Nguyen, Jaesung Seo, Min Wu, Tessa Seale, Mark Levis, Amy Duffield, Yu Hu, Donald Small

发表日期：2021

文献求助收藏

Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera

血小板生成素是真性红细胞增多症 JAK2V617F 转基因小鼠模型中完全表型表达所必需的

期刊:PLoS One

影响因子:2.9

doi:10.1371/journal.pone.0232801

Jerry L Spivak, Akil Merchant, Donna M Williams, Ophelia Rogers, Wanke Zhao, Amy Duffield, Linda S Resar, Alison R Moliterno, Zhizhuang J Zhao

发表日期：2020

文献求助收藏

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3

ATO 与 FLT3 TKI 联合使用可通过降低 FLT3 表达来消除 FLT3/ITD+ 白血病细胞

期刊:Oncotarget

doi:10.18632/oncotarget.25972

Kozo Nagai #, Lihong Hou #, Li Li, Bao Nguyen, Tessa Seale, Courtney Shirley, Hayley Ma, Mark Levis, Gabriel Ghiaur, Amy Duffield, Donald Small

细胞生物学

发表日期：2018

文献求助收藏

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo

TTT-3002 是一种新型 FLT3 酪氨酸激酶抑制剂，在体外和体内均具有抗 FLT3 相关白血病的活性

影响因子:21

doi:10.1182/blood-2013-08-523035

Hayley Ma, Bao Nguyen, Li Li, Sarah Greenblatt, Allen Williams, Ming Zhao, Mark Levis, Michelle Rudek, Amy Duffield, Donald Small

发表日期：2014

文献求助收藏

Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model

FLT3/ITD 突变敲入与 NUP98-HOXD13 融合协同在小鼠模型中产生急性髓系白血病

影响因子:21

doi:10.1182/blood-2011-10-382283

Sarah Greenblatt, Li Li, Christopher Slape, Bao Nguyen, Rachel Novak, Amy Duffield, David Huso, Stephen Desiderio, Michael J Borowitz, Peter Aplan, Donald Small

发表日期：2012

文献求助收藏